Instil Bio (TIL) AI Stock Analysis

• Market Cap: $145.44M
• Dividend Yield: N/A
• Average Volume (3M): 141.30K
• Price to Earnings (P/E): ―
• Beta (1Y): 4.94
• Revenue Growth: N/A
• EPS Growth: 29.72%
• Country: US
• Employees: 14
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -3.24
• Shares Outstanding: 6,750,716
• 10 Day Avg. Volume: 214,671
• 30 Day Avg. Volume: 141,299
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.90
• Enterprise Value/Revenue: 32.70
• Enterprise Value/Gross Profit: 223.54
• Enterprise Value/Ebitda: -1.65
• 1Y Price Target: $125.00
• Price Target Upside: 494.39% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 34 Underperform
• Price Target: ―

Instil Bio's stock faces considerable challenges primarily due to severe financial instability, as evidenced by the absence of revenue and ongoing losses. The technical analysis indicates a bearish trend, with the stock significantly underperforming compared to its moving averages. Additionally, the company’s valuation metrics, including a negative P/E ratio and no dividend yield, further underscore the high risk associated with this investment. These factors combine to give Instil Bio a low overall stock score.

Positive Factors

Strategic Partnerships

The collaboration with ImmuneOnco for clinical trials of AXN-2510/IMM2510 can enhance Instil Bio's market position and accelerate product development, potentially leading to new revenue streams and strengthening its competitive edge in oncology.

Liquidity Position

A strong cash position offers Instil Bio the liquidity needed to fund ongoing operations and strategic initiatives, providing a buffer against financial instability and supporting long-term growth efforts in the biotechnology sector.

Industry Positioning

Upcoming clinical developments in 2025 could enhance Instil Bio's positioning in the biopharmaceutical industry, potentially leading to breakthroughs in cancer therapy and establishing the company as a leader in innovative oncology solutions.

Negative Factors

Revenue Generation Challenges

The lack of revenue generation indicates significant challenges in monetizing technology or products, posing a risk to long-term financial sustainability and the ability to invest in future growth without external funding.

Negative Cash Flow

Persistent negative cash flow from operations highlights ongoing financial strain, necessitating additional financing to maintain operations and potentially leading to increased financial risk if not addressed.

Equity Financing Risks

Heavy reliance on equity financing may lead to shareholder dilution, affecting investor returns and indicating a need for sustainable revenue generation to reduce dependency on external capital.

Instil Bio Business Overview & Revenue Model

Company Description

Instil Bio is a biotechnology company focused on developing innovative cancer therapies. Specializing in tumor-infiltrating lymphocyte (TIL) technology, Instil Bio is dedicated to advancing cell therapy treatments that harness the power of the immune system to combat solid tumors. The company operates in the biopharmaceutical sector, aiming to provide novel therapeutic options for patients with unmet medical needs in oncology.

How the Company Makes Money

Instil Bio generates revenue primarily through the development and commercialization of its TIL-based therapies. The company may enter into strategic partnerships and collaborations with other biotech firms, research institutions, or pharmaceutical companies to co-develop and commercialize therapies, which can include upfront payments, milestone payments, and royalties based on sales. Additionally, as its products move through clinical trials and, if successful, receive regulatory approval, revenue can be generated from the sale of these therapies to healthcare providers and institutions treating cancer patients. Other potential revenue streams could include licensing its technology to other companies in the biotechnology and pharmaceutical sectors.

Instil Bio Financial Statement Overview

Summary

Instil Bio is facing significant financial challenges, characterized by no revenue generation, ongoing losses, and negative cash flows. While the balance sheet shows liquidity strength, the reliance on equity financing poses dilution risks. The company's financial health is precarious, requiring substantial strategic shifts to achieve sustainable operations.

Income Statement

Instil Bio has reported no revenue for several consecutive years, indicating significant challenges in monetizing its technology or products. The absence of revenue coupled with consistent and substantial net losses highlight severe profitability issues. Although there is a reduction in net loss from the prior year, the company still faces major financial hurdles.

Balance Sheet

The company maintains a reasonable cash position with cash and short-term investments of $113 million, providing some liquidity. However, the debt-to-equity ratio is low due to minimal debt, which is a positive. The equity ratio indicates a strong reliance on equity financing, suggesting potential dilution risks for investors. Overall, the balance sheet shows liquidity strength but significant equity erosion over time.

Cash Flow

Operating cash flow remains deeply negative, reflecting ongoing operational losses. There is a notable decrease in negative free cash flow from the previous year, indicating some improvement in cash management. However, consistent negative cash flow from operations poses a significant risk to financial sustainability without additional financing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.99M	0.00	0.00	0.00	0.00	138.00K
Gross Profit	583.00K	-3.61M	-4.76M	-5.99M	-2.75M	138.00K
EBITDA	-79.04M	-61.53M	-146.12M	-217.38M	-154.00M	-33.39M
Net Income	-84.51M	-74.14M	-156.09M	-223.18M	-156.79M	-37.74M
Balance Sheet
Total Assets	230.99M	263.57M	325.63M	482.13M	609.98M	319.01M
Cash, Cash Equivalents and Short-Term Investments	91.82M	113.31M	150.36M	260.92M	454.10M	241.71M
Total Debt	6.00K	86.89M	86.05M	79.90M	0.00	0.00
Total Liabilities	99.32M	94.13M	99.80M	118.52M	54.78M	358.61M
Stockholders Equity	131.67M	169.44M	225.83M	363.61M	555.20M	-39.60M
Cash Flow
Free Cash Flow	-43.31M	-55.70M	-102.69M	-264.75M	-179.97M	-80.43M
Operating Cash Flow	-43.31M	-55.70M	-82.03M	-180.16M	-122.14M	-29.62M
Investing Cash Flow	38.64M	53.97M	41.13M	114.54M	-474.40M	-51.12M
Financing Cash Flow	7.30M	1.75M	8.08M	71.89M	393.16M	313.05M

Instil Bio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 21.03
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TIL, the sentiment is Negative. The current price of 21.03 is below the 20-day moving average (MA) of 26.19, below the 50-day MA of 26.67, and below the 200-day MA of 22.65, indicating a bearish trend. The MACD of -1.26 indicates Positive momentum. The RSI at 37.54 is Neutral, neither overbought nor oversold. The STOCH value of 7.56 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TIL.

Instil Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ZURA	43 Neutral	123.53M	-2.70	0.00%	―	0.00%	-50.20%
NKTX	39 Underperform	135.66M	-1.34	0.00%	―	0.00%	26.33%
TNYA	36 Underperform	198.83M	-1.37	0.00%	―	0.00%	38.94%
KYTX	36 Underperform	188.98M	-1.36	0.00%	―	0.00%	-39.69%
TIL	34 Underperform	$145.44M	―	-51.74%	―	―	29.72%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Instil Bio Corporate Events

Instil Bio Reports 2024 Financial Results and Outlook

Instil Bio reported its fourth quarter and full year 2024 financial results, highlighting a decrease in cash and marketable securities compared to the previous year. The company anticipates significant clinical developments in 2025, including data updates and trial initiations for its lead asset AXN-2510/IMM2510 in collaboration with ImmuneOnco, which could impact its operations and industry positioning.